New drug cocktail shows promise for rare blood cancers
NCT ID NCT03240211
First seen Apr 14, 2026 · Last updated May 08, 2026 · Updated 3 times
Summary
This early-phase study tests a combination of three drugs (pembrolizumab, decitabine, and pralatrexate) in adults with relapsed or refractory peripheral T-cell lymphoma or cutaneous T-cell lymphoma. The main goals are to find the safest dose and see if the treatment shrinks tumors. About 37 participants will take part across multiple centers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CTCL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allegheny Health Network
Pittsburgh, Pennsylvania, 15212-4722, United States
-
University of Virginia
Charlottesville, Virginia, 22911, United States
Conditions
Explore the condition pages connected to this study.